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THE DEVELOPMENT OF more cost-effective light sources for photodynamic therapy of brain tumors would be of 
benefit for both research and clinical applications. In this study, the use of light-emitting diode arrays for 
photodynamic therapy of brain tumors with Photofrin porfimer sodium was investigated. An inflatable balloon 
device with a light-emitting diode (LED) tip was constructed. These LEDs are based on the new semiconductor 
aluminum gallium arsenide. They can emit broad-spectrum red light at high power levels with a peak wavelength of 
677 nm and a bandwidth of 25 nm. The balloon was inflated with 0.1 % intralipid, which served as a light-scattering 
medium, Measurements of light flux at several points showed a high degree of light dispersion, The spectral emission 
of this probe was then compared with the absorption spectrum of Photofrin. This analysis showed that the light 
absorbed by Photofrin with the use of the LED source was 27,5% of that absorbed with the use of the monochro-
matic 630-nm light. Thus, to achieve an energy light dose equivalent to that of a laser light source, the LED light 
output must be increased by a factor of 3.63, This need for additional energy is the difference between a 630- and 
677-nm absorption of Photofrin. Using the lED probe and the laser balloon adapter, a comparison of brain stem 
toxicity in canines was conducted, LED and laser light showed the same signs of toxicity at equivalent light energy 
and Photofrin doses. The maximal tolerated dose of Photofrin was 1.6 mg/kg, using 100 )/cm2 of light energy 
administered by laser or LED. This study concludes that lEDs are a suitable light source for photodynamic therapy 
of brain tumors with Photofrin. In addition, LEDs have the potential to be highly efficient light sources for 
second-generation photosensitizers with absorption wavelengths closer to the lED peak emission. (Neurosurgery 
38:552-557, 1996) 
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Photodynamic therapy (PDT) is a relatively new adjuvant treatment for brain tumors in research and clinical prac-tice (1O, 13-15, 17, 21, 23, 24, 29). The cytotoxic photo-
dynamic effect is based on the interaction of localized photo-
sensitizer, light, and oxygen (8). For PDT of brain tumors, the 
most commonly used photosensitizer is Photofrin porfimer 
sodium (22). Photofrin, a heterogeneous mixture of hemato-
porphyrin, preferentially accumulates in brain rumors (9, 12, 
28, 29). The absorption spectrum of Photofrin is relatively 
broad, with two significant absorption peaks, a major absorp-
tion peak at 390 nm and a minor absorption peak at 630 nm 
(11). Traditionally, red laser light with a 630-nm wavelength 
has been used to activate Photofrin because of the increased 
tissue penetration of light at longer wavelengths. Red laser 
light is frequently produced by using an argon ion or KTP / 
Y AG lilser beam that is converted by a dye module to 630 nm. 
This conversion is inherently costly and inefficient but allows 
for light delivery with fiberoptics. For nonfiberoptic applica-
tion of light, other light sources could potentially be useful 
alternatives. 
In this study, ... we investigated the use of light-emitting 
diodes (LEOs) -as a new light source for PDT. LEOs have 
frequently been used to emit low-power, broad-spectrum 
light of 25- to 3D-nm bandwidth for photosynthesis research in 
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plants (1,2,25). LED Jamps traditionally consist of an array of 
semiconducting LED chips. In recent years, improvements in 
semiconductor technology have substantially increased the 
light output of LED chips. A novel type of LED chip is based 
on the semiconductor aluminum gallium arsenide. Depend-
ing on the amount of gallium and aluminum in the LED chip, 
the peak wavelength can be between 630 and 940 nm with a 
wide bandwidth of 20 to 25 nm (2, 25). The broad emission 
spectrum of the LED overlaps with the absorption spectrum 
of photosensitizers used for PDT of brain tumors. 
The objective of this study was to describe the use of LED 
arrays for PDT with Photofrin. The hypothesis of this 
investigation was that Photofrin can be activated by broad-
spectrum LED light at a light energy dose equivalent to that of 
a 630-nm laser light source. In addition, a new light delivery 
device that uses LEOs as a light source was developed. 
MATERIALS AND METHODS 
LED probe for in vivo study 
To deliver LED light in vivo and compare it with the light 
of a conventional laser balloon adapter, a LED probe was 
constructed (Fig. 1). The LED probe consists of a 10-cm hollow 
steel tube that has 144 LED chips arranged in a cylinder at the 
tip. The core of the tube contains three channels. One channel 
contains insulated wires that provide electricity for the LED 
tip. The other channel is filled with sterile water as a cooling 
t1uid, which is circulated around the tip. An additional port 
provides access for the 0.1 % intralipid fluid to inflate the latex 
balloon at the tip. The pump for the cooling t1uid and the 
power supply are in a portable base unit. The power output of 
the LED tip is adjusted via a potentiometer at the base unit, 
which increases the current flow. The temperature at the tip 
was continuously monitored and kept below 37°C at all times. 
To ~oollog fluid loop and LEIl power from portable conlrol console 
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FIGURE 1. The LED balloon applicator in a schematic 
overview. 
Light-emitting Diodes 
Spectral analysis of Photofrin and the LED 
A spectral comparison of the LED probe and Photofrin 
(QuadraLogic Technologies, Vancouver, B.c., Canada) was 
performed. We obtained the absorption spectrum of Photofrin 
by dissolving Photofrin in a phosphate solution. The percent 
absorption was determined using 630-nm absorption as a 
reference point (100%). The emission spectrum of the LED 
probe was measured with a spectrophotometer. The peak 
emission of 677 nm was used as a reference point. The final 
curve (LED jPhotofrin) was obtained by multiplying the 
percent of Photofrin absorption with the percent of LED 
emission. 
light measurements 
The balloon of the LED probe was inflated with a 0.1% 
intralipid solution. The balloon diameter ranged from 2 to 5 
cm. The tip of the LED probe was placed in the center of the 
balloon. The total power output was 1.0 W at the tip and was 
kept constant for all measurements. A light-detecting probe 
(Cuda Products Corp., Jacksonville, FL) was then used to 
measure the light irradiance at several points on the balloon 
surface. The light~detecting probe consisted of an optical fiber 
with a 3-mm diameter. Measurement points were selected at 
the front and back of and at 45, 90, 135,0, -45, -90, and -135 
degrees around the LED probe axis. The light measured by 
the detecting probe was transmitted via an optical fiber to an 
integrating sphere (Model 2525; Graseby Optronics, Orlando, 
FL), which contained a sensor head (Model 247i Graseby 
Optronics). The sensor head was coupled to a single-channel 
optometer (System S370; Graseby Optronics). 
Photodynamic studies in vivo 
Adult mongrel dogs weighing approximately 20 kg were 
used for in vivo PDT. All animals were intubated and placed 
under general anesthesia using a mixture of halothane and 
nitrous oxide. The head of each canine was securely fixed to a 
head frame and maximally flexed. Using a posterior ap-
proach, we exposed the suboccipital bone and the Cl verte-
bra. A wide craniectomy was performed using a power drill. 
A Y -shaped dural incision exposed the cerebellum, the lower 
brain stern, and the upper cervical spinal cord. The balloon 
applicator with a diameter of 2 cm was placed into the pos-
terior fossa on the brain stem. Self-retaining retractors were 
used to secure the baBoon applicator to prevent excessive 
pressure on the brain stem. All dogs (except for light-only 
controls) received Photofrin 24 hours before light exposure in 
increasing doses starting from 0.75 rug/kg. The maximum 
tolerated dose)MTD) was defined as the dose given to the 
group of canines that preceded the group with a 50% neuro-
toxicity rate. Group 1 received laser light and Phatofrin. 
Group 2 received LED light and Photofrin. Each group had 
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light-only controls. The LED balloon adapter was adjusted to 
deliver 363 J/cm2 for an animals receiving LED light. The 
laser light Was produced by an Aurom/M laser system (La-
sersonics, Inc., Santil Clara, CA), which was tuned to a 630-nm 
wavelength. 
RESULTS 
Spectral comparison results 
The spectral analysis graphs are illustrated in Figllre 2. 
CUrll1! A represents Photofrin absorption relative to 630 nm. It 
can be appreciated that at 677 nm, Photofrin light absorption 
is only 25% of that at 630 nm. Curve B shows the emission 
spectrum of the LED probe relative to 677 nm, its peak wave-
length. The final curve, C, is derived by multiplication of the 
relative 677-nm LED spectral emission and the relative 
630-nm Photofrin absorption across the entire spectrum. Cal-
culation of the total LED absorption reltltive to a 630-nm laser 
source is performed by comparison of the integration of the 
LED emission spectrum with the integration of the LED/ 
Photofrin absorption spectrum. This calculation yielded a 
27.5% total absorption of the 677-nrn LED spectrum, as com-
pared with the 630-nm LED spectrum. The results of these 
calculations indicate that 3.63 times more joules of energy 
from a 677-nm LED source would be required to generate an 
equivalent absorption result, as compare<.i with a 630-nm 
monochromatic light source. This need for additional energy 
is the difference of absorption between 630 and 677 nm for 
Photofrin. 
Light uniformity 
The lipid-filled balloon was able to uniformly SCilUer the 
LED light. The measurements of light used with the detectin.g 
probe are shown in Table 1. The average light irradiation was 
within 20% of the average light output. In addition, it seems 
FIGURE 2. Spectral comparison of LED and Photo!rin. Pho-
to!rin absorption of 677-nm LED relative to 630-nm absorp-
tion line. A, Photofrin absorption curve relative to 630 nm. 
B, spectral emission of the LED. C, integration of the LED 
spectral emission and the Photofrin absorption. 
TABLE 1. light Irradiance of light-emitting Diode 
Probe (mW) 
Balloon Diameter 
2cm 3 em 4 ern 5 em 
Front 1.441 0.6311 0.460 0.256 
Back 1.751 0.958 0.491 O.2BO 
135 degrees 1.213 0.595 0.365 0.242 
90 degrees 1.521 0.719 0.454 0.271 
45 degrees 1.425 0.740 0.425 0.225 
o degrees 1.703 0.B43 0.430 0.19B 
-45 degrees 1.675 O.BOO 0.491 0.249 
-90 degrees 1.725 0.921 0.559 0.261 
-135 degrees 1.217 0.620 0.432 0.249 
Mean 1.525 0.7595 0,456 0.247 
Minimum (%) 20.4 21.7 19.9 19.B 
Maximum (u;:)) 14.8 26.1 21.6 13.4 
TABLE 2. Summary of Canine Brain Stem T oxicily Study'") 
Number Clinical MRI 
of Dogs Toxicity 
Laser ilnd Photofrin 
lighl only 2 none nl 
0.75 (, nOlle nl 
1 " 3 none nl 
1.6 none nl 
2.0 2 transient nl 
3.0 dealh 
LED and Pholofrin 
Lighlonly 1 none nl 
1.6 3 none nl 
2.0 2 transient nl 
3.0 0 
<1 MRI, magnetic resonance imaging; lED, light-emitting diode;~, not 
applicable. 
that the degree of uniformity remained constant with the 
increasing diameter of the balloon. 
PDT in vivo 
The results of PDT in canines are summarized in Table 2. 
The MTD for Group 1, which received the LED/Photofrin 
combination, WilS 1.6 mg/kg. The same MTD was obtained in 
Group 2, which received the laser/Photofrin combination. 
Light only, whether laser or LED, did not cause any signifi-
cant neurological deficits at the power levels used. At doses 
higher than 2.0 mg/kg Photofrin, no dog survived longer than 
4 hOllrs after PDT. Death was secondilry to respiratory arrest 
from brain stem damage. At doses of 2.0 mg/kg Photofrin, 
neurological deficits were transient. Hind leg weakness and 
head tilt were /1oted for a period of 1 week but then com-
pletely resolved. The magnetic resonance imaging scans re-
vealed no significant lesions in animals that survived the 
treatment. 
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DISCUSSION 
Photofrin is the most frequently used photosensitizer in 
experimental and clinical studies for brain tumors (21). This 
mixture of hematoporphyrin compounds exhibits a broad 
spectrum of absorption with several distinct absorption 
peaks. Traditionally, the art of energizing Photofrin required 
using a 630-nm laser as the light source. The reasons for 
choosing this wavelength arc twofold. Photofrin has a minor 
absorption peak in the red region of its absorption spectrum. 
In addition, in brain tissue, light penetration is deeper with 
increasing wavelength (3, 4, 20). Argon ion and KTP jYAG 
dye lasers have been able to provide 630-nm wavelength light 
with narrow bandwidth at power levels sufficient to activate 
Pholofrin. Nevertheless, narrow bandwidth light is not nec-
essary to activate Photofrin. 
Developing new light sources and light delivery devices is 
critically important for PDT. In this Shldy, a LED probe with an 
inllatable tip was constructed and compared with the laser bal-
loon adapter. The concept of using a lluid-filled balloon to pho-
toilIuminate a tumor cavity after maximal resection was origi-
nally presented by Muller and Wilson (18-21) and Wilson et aJ. 
(30). They developed a laser balloon adapter in which the red 
laser light is delivered via a fiberoptic to the center of a fluid-
filled balloon. TIle fluid inside the balloon serves as a light-
scattering medium. fn addition, the inflated balloon prevents the 
collapse of the resection cavity, which potentially could preclude 
light from reaching residual tumor cells. The LED probe is 
similar in that a fluid-filIet.:l balloon is used as a light-scattering 
medium. In contrast, the LED probe does not require a fiberoptic 
for light delivery. Fiberoptics create a substantial loss of power 
between the laser light source and the target tissue; the power 
loss can be as great as 50%. The red light of the LED probe is 
produced at the tip in the center of the balloon. Thus, there is no 
loss in power as for fiberoptic transmission. This makes LED a 
more efficient red light source. 
The light output of the laser balloon adapter is directed for-
ward as the laser light exits the optical fiber and then is scattered 
by the intralipid balloon fluid (30). In contrast, the LED tip is 
cylindrical and, combined with the intra lipid in the balloon, 
provides reasonable spherical unifonnity of light distribution. 
Light flux measurements showed that the LED light output with 
the inflated intralipid-filled bnlloon is within 20% of the average 
power output. 111is compares favorably with the light distribu-
tion of the laser balloon adapter (30). 
Another difference between the laser balloon adapter and 
the LED probe is their emission spectra. The laser produces 
630-nm light of narrow bandwidth (1-2 nm). The LED, in 
contrast, produces a red light of broad spectrum with a peak 
wavelength of 677 nm and a bandwidth of 25 nm. The spectral 
comparison of the LED with the absorption spectrum shows 
that a significant amount of the spectral emission of the LED 
is available for absorption by Photofrin. Specifically, 27.5% of 
the LED spectral output is absorbed, as compared with a 
630-nm light source. This difference in absorption results in a 
decrease of absorbed energy for photodynamic effect. The 
LED power output can be easily increased to provide an 
equivalent energy. Thus, the data indicate that Photofrin can 
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absorb light of multiple wavelengths at a light energy dose 
equivalent to that of 630-nm monochromatic laser light. Be-
cause the photodynamic effect depends on the light energy 
dose and not directly on the wavelength, an equivalent phoR 
todynamic effect is expected (5, 6, 8). Our in vivo brain stem 
toxicity study confirmed the hypothesis. The MTD of Photo-
frin was 1.6 mg/kg, using 100 II cm2 of light energy. LED and 
Inser light showed the same signs of toxicity at equivalent 
light energy and Photofrin doses. This indicates that equiva-
lent light energy doses, as determined by spectral comparison 
of laser light and LED light, have similar photodynamic ef-
fects. In addition, the broadRspectrum light provides the op-
portunity for Photofrin to absorb light at longer wavelengths. 
Thus, LED light can potentially activate Photofrin in deeper 
tissues as compared with monochromatic 630-nm laser light. 
LEDs can also be used to activate photosensitizers other 
than Photofrin. Currently, several second-generation photo~ 
sensitizers are under development (7). These include bacte-
riochlorins, substituted porphyrins, chiorins, naphthalocya-
nines, purpurins, phthalocyanines, and benzoporphyrin 
derivatives. The advantages of these second-generation pho-
tosensitizers over Photofrin include longer absorption wave-
lengths, higher singlet oxygen yields, and decreased skin 
phototoxicity. The peak absorption wavelength of benzopor-
phyrin derivative and some of the phthalocyanines are 690 
nm and 675 nm, respectively (7, 16, 27). LEDs can produce 
light with corresponding peak emission wavelengths. There-
fore, the LED potentially is a very efficient light source for the 
second generation of photosensitizers. Although laser light is 
available at these longer wavelengths, the use of LEDs as a 
light source is much more economical because they are avail-
able at a fraction of the cost of lasers. An efficient, yet cost-
effective, light source, such as the LED, could greatly increase 
the research of and clinical interest in PDT with long wave-
length photosensitizers. 
Recently, the wavelength~dependent effects of benzoporphy-
rin derivative have been investigated (27). Phototoxicity was 
assessed in vitro and in vivo at several monochromatic wave-
lengths ranging from 678 to 700 nm. The results indicate that 
there was an equivalent phototoxic effect over a range of wave-
length. 111is suggests that light sources with broad-spectrum 
output, such as the LED, might have equivalent efficacy. 
CONCLUSION 
LEDs can efficiently provide broad-spectrum red light for 
PDT with Photofrin. The LED balloon adapter is a new light 
delivery device that could be used for intracavitary PDT of 
brain tumors. We are currently investigating PDT with PhoR 
tofrin in a canine brain tumor model using the LED probe. In 
addition, we are studying the use of LEDs with new photoR 
sensitizers, such as benzoporphyrin derivative and phthalo~ 
cyanines, that have major absorption peaks closer to the cen-
tral emission wavelength of the LED spectrum. 
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COMMENTS 
Schmidt et al. describe the development of an inflatable 
balloon device fitted with light-emitting diodes (LEDs), which 
may have appIicCltion uS a light source for photodynamic 
therapy (PDT) of brain tumors. The authors correctly observe 
that "the development of more cost-effective light sources for 
PDT of brain tumors would be of benefit for both research and 
clinical application." 
In the clinical situation, lasers have generally been the most 
commonly used light sources for PDT of brain tumors, al-
though incand~8cent sources have also been used with a 
variety of techniques to deliver the light to the tumor. DeJiv~ 
ery techniques have included the use of a flat-cut optical fiber 
held in place by a retraction arm and suspended in the resec-
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tion cavity filled with intra lipid (1, 2), the use of an inflatable 
intralipid-fil1ed balloon applicator containing an optical fiber 
placed in the cavity (4, 5), the stereotactic implantation of 
fibers (3, 6), and shining of incandescent light directly on the 
tumor bed. Although lasers have until now been the light 
sources of choice, the potential for lower-cost, more efficient 
LED sources offers considerable promise. The studies re-
ported in this article combine the advantages of an aluminum 
gallium arsenide LED array with the intracavitary balloon 
device developed by Muller and Wilson (4, 5). However, the 
LED array has a maximum spectral output at 675 nm and a 
poor spectral output at 630 nm (Fig. 2 in article). Thus, the real 
potential for the device described here is probably not as an 
irradiation source to activate either hematoporphyrin deriva-
tive or Photofrin, but rather as a source to activate the poten-
tial new "second-generation" sensitizers with peak absorption 
wavelengths in the range of 650 to 750 nm, which have a 
much longer penetration through brain and tumor. The work 
reported by Schmidt et al. is important, as the development of 
such sources is necessary before Phase III trials of PDT as an 
adjuvant therapy for cerebral glioma, using new sensitizers 
with longer wavelengths of absorption, can be undertaken. 
John S. Hill 
Andrew H. Kaye 
Melbol/rne, Australia 
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Light-emitting Diodes 557 
The investigators present a novel device, namely a LED 
array for the purpose of cavitary photoillurnination for brain 
tumor PDT. The device creates virtually uniform surface ir-
radiance, is volume expandable, and has a wavelength spec-
tmm appropriate to the activation of the most popular pho-
tosensitizer in clinical use (porfimer sodium, Photofrin). 
Photofrin activation increases with decreasing wavelength, 
but the tissue penetration of photic energy increases with 
increasing wavelength. Thus, the wavelength of 630 nm has 
been used for PDT because it is the last peak in the sensitizer's 
absorption spectrum. The authors showed that Photofrin light 
absorption with the LED device was 28% of the absorption 
achieved with monochromatic 630-n111 light; however, the 
reduced absorption could be off set by increasing the total 
photic energy output of the LED array. 
The photoillurnination of brain tumor tissue by laser light 
has been the method of choice, because monochromatic, 
coherent light can be coupled to optical fibers and thus 
directed to the target tissue; laser applications have also 
allowed a relatively accurate dosimetry. Disadvantages of 
laser technology are the capital cost and the maintenance 
requirements. The introduction of effective alternate light 
sources will significantly enhance the application of brain 
tumor PDT. 
Paul J. Muller 
Torollto, Ollfario, Canada 
This article represents a simple, clean experimental de-
sign set up to study the question of whether non-laser-
dependent alternative light sources can be used for photo-
activation of porphyrin-based PDT. The authors have 
successfully designed a device that is not dependent upon 
expensive, technically complicated lasers. These devices 
also offer the opportunity to be used on a large variety of 
new photosensitizers that are currently coming into exper-
imental and clinical use. Technical breakthroughs such as 
these will allmv progress to be made in the application of 
innovative treatments to difficult clinical problems, such as 
the treatment of brain tumors. 
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